Avastin (bevacizumab) / Roche - LARVOL DELTA

Efficiency of anti-vascular endothelial growth factor drug switch in patients who did not respond to a series of bevacizumab injections. (PubMed, Indian J Ophthalmol) - "Switching anti-VEGF agents appears anatomically beneficial in nonresponding eyes. Notably, the inclusion of a control group continuing bevacizumab despite poor response allows for a more reliable evaluation of treatment efficacy, addressing a key limitation of prior studies and contributing to the evidence-based rationale for agent switching."

Journal • Age-related Macular Degeneration • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Long-term safety and effectiveness of systemic bevacizumab for chronic severe bleeding in idiopathic gastrointestinal angiodysplasia, esophageal varices, and angiodysplasia of von willebrand disease and acquired von willebrand syndrome (ASH 2025) - "View Abstract"

Clinical • Cardiovascular • Gastroenterology • Hemophilia

Real world evidence of treatment patterns in hereditary hemorrhagic telangiectasia (ASH 2025) - "Treatment examinedincluded bevacizumab, pazopanib, pomalidomide, aminocaproate, tranexamic acid (TXA), octreotide,lanreotide, thalidomide, tacrolimus, sirolimus, tamoxifen and raloxifene...The majority of HHT patients were treated withferrous sulfate (n=910), followed by iron sucrose, ferrous gluconate, ferric carboxymaltose, iron dextran,and ferric derisomaltose...While 8% of patients treated with TXA had VTE, the data does not support a definitiveconclusion of increased VTE in patients treated with anti-fibrinolytics. To further elucidate treatmentpractices in HHT, a multi-center approach incorporating review of medical records would providevaluable insights into real-world practices."

Clinical • HEOR • Real-world • Real-world evidence • Anemia • Aplastic Anemia • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Renal Disease • Venous Thromboembolism

Impact of VEGF inhibition on the development of erythrocytosis in hereditary hemorrhagic telangiectasia (ASH 2025) - "However, in clinicalpractice, erythrocytosis has been observed in some HHT patients treated with bevacizumab, includingthose without PAVMs or in those who had already undergone embolization...Overall, these findings highlight the importance of monitoring hemoglobin levels duringtreatment and support a more comprehensive evaluation of patients who develop erythrocytosis whichmay have been masked by prior frequent bleeding. Detailed evaluations of erythrocytosis should includeJAK2 mutation testing, EPO measurement, and consideration of other causes of secondaryerythrocytosis."

Cardiovascular • CNS Disorders • Hematological Disorders • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder • Thrombosis • ACVRL1 • JAK2

CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis (ASH 2025) - "We hypothesized that by protecting HSPCs from the cytotoxic effects of chemotherapy,trilaciclib might also reduce the clonal expansion of TP53-mutant CH during chemotherapy.We obtained serial blood samples from healthy controls (n=176) and three placebo-controlledrandomized clinical trials of trilaciclib including patients with (1) SCLC (n=65) receiving carboplatin andetoposide, (2) metastatic colorectal cancer (mCRC) (n=125) receivingleucovorin/fluorouracil/oxaliplatin/irinotecan (FOLFOXIRI) plus bevacizumab, and (3) metastatic triplenegative breast cancer (mTNBC) (n=34) receiving gemcitabine and carboplatin...Similar effectswere seen with the oral CDK4/6 inhibitor palbociclib and using a dominant negative form of CDK6introduced into p53 mutant HSPCs.Single cell RNA-seq of chimeric mice treated with carboplatin with trilaciclib or single agent controlsrevealed that CDK4/6 inhibition treatment promotes HSC and myeloid progenitor quiescence whilemitigating the myeloid..."

Breast Cancer • Colorectal Cancer • Eye Cancer • Hematological Malignancies • Lung Cancer • Retinal Disorders • Retinoblastoma • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer • PTPRC • TP53

Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection. (PubMed, MAbs) - "We demonstrate that co-transfection of heavy and light chain mRNAs enables the efficient synthesis, assembly and secretion of the monoclonal antibody bevacizumab with high fidelity. Compared to conventional approaches, mRNA transfection drives rapid and predictable protein expression, reducing cell incubation times and enabling sequential or conditional expression. These features highlight mRNA as a flexible and efficient platform for transient expression, providing a foundation for accelerating the development and manufacturing of biologics."

Journal

Atypical hemolytic uremic Syndrome Triggered by malignancy and drug exposure: A systematic review and meta-analysis (ASH 2025) - "Tacrolimus was the mostreported drug trigger (n=6)followed by gemcitabine (n=5), vincristine (n=5), bevacizumab (n=3), carfilzomib (n=3), 6-mercaptopurine(n=2), methotrexate (n=2), and mitomycin (n=2). Aflibercept, bactrim, bleomycin, capecitabine, cisplatin, cyclophosphamide, cytarabine,dasatinib, deferasirox, dinutuximab, estarylla, ketoprofen, L-asparaginase, modakafusp alfa, PEG-asparaginase, sunitinib, syntheticpsychoactive drugs, tamoxifen, and topotecan were reported as potential triggers for aHUS in one patient each...The pooled rate of treatment with eculizumab was 74% (95% CI, 0.629-0.842, p < 0.01, I2 = 72%),and the pooled rate of renal recovery was 65% (95% CI, 0.525-0.761, p < 0.01, I2 = 55%)...AKI and hematological abnormalities in these patients should prompt an emergent work-up and treatment. Current evidenceis primarily derived from case reports, so prospective trials are necessary to establish the incidence, associations, triggers, and outcomes..."

Retrospective data • Review • Acute Kidney Injury • Acute Lymphocytic Leukemia • Anemia • Atypical Hemolytic Uremic Syndrome • B Acute Lymphoblastic Leukemia • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Complement-mediated Rare Disorders • Genito-urinary Cancer • Hematological Malignancies • Hepatocellular Cancer • Hodgkin Lymphoma • Leukemia • Lung Cancer • Lymphoma • Multiple Myeloma • Nephrology • Neuroblastoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Renal Disease • Solid Tumor • Thrombocytopenia • Urothelial Cancer

Overall survival (OS) in patients with metastatic colorectal cancer (mCRC) following persistent chemotherapy-induced thrombocytopenia (pCIT) (ASH 2025) - "pCIT was defined as the first occurrence of a platelet countmeasurement ≤85×109/L, ≥13 days after the nearest prior chemotherapy administration with fluorouraciland oxaliplatin (FOLFOX) or fluorouracil, irinotecan, and oxaliplatin (FOLFOXIRI); or ≥ 20 days afteroxaliplatin and capecitabine (CAPOX)... The median OS for mCRC patients following the first pCIT ranges from 9.7 to 23.5 months,with 6-month survival probabilities between 64% and 90%, across different LOTs. Multiple factors, suchas LOT, ECOG, age, CIT grade, and bevacizumab use, are associated with clinically relevant differences insurvival in patients with pCIT. These findings provide clinically relevant benchmarks for survival and maybe useful in assessing the need for supportive therapy."

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor • Thrombocytopenia

Long-term safety and effectiveness of systemic bevacizumab for chronic severe bleeding in idiopathic gastrointestinal angiodysplasia, esophageal varices, and angiodysplasia of von willebrand disease and acquired von willebrand syndrome (ASH 2025) - "Threepatients (13%) discontinued for TEAEs (all grade 3 proteinuria) and 5 (22%) discontinued for inadequatetreatment effect.ConclusionsIn this study, systemic bevacizumab was safe and highly effective in treating severe chronic bleeding fromGI vascular lesions across a wide variety of non-HHT etiologies, including idiopathic angiodysplasia,esophageal varices, von Willebrand disease and acquired von Willebrand syndrome in a highly comorbidmostly older adult/late elderly population. Systemic bevacizumab may be a novel therapeutic option forclinically challenging vascular bleeding outside of HHT."

Clinical • Cardiovascular • Gastroenterology • Hematological Disorders • Hemophilia • Hypertension • Renal Disease • DLAT

fss25-67: Advances in Targeting Angiogenesis and Managing Severe Anemia in Vascular Bleeding Disorders:Hereditary Hemorrhagic Telangiectasia, Von Willebrand Disease, and Beyond (ASH 2025) - "This symposium will discuss the role of angiogenesis in these bleeding disorders, how to optimally manage this bleeding with anti-angiogenic agents such as bevacizumab, pomalidomide, and pazopanib, and how to properly manage the complex and difficult chronic, severe iron deficiency anemia that complicates the course of these patients. Current and future potential antiangiogenic and coagulation-based treatments will be discussed by international leaders in the field."

Anemia • Hematological Disorders • Hemophilia

Ivonescimab for EGFR-mutant lung adenosquamous carcinoma after multiline therapy: A case report. (PubMed, Front Oncol) - "Despite initial responses to first-line firmonertinib-based combination therapy, progression-free survival (PFS) 13 months, the patient developed sequential resistance to subsequent regimens, including liver/brain metastases and treatment-related toxicities. After fourth-line therapy failure and severe intolerance to albumin-bound paclitaxel and bevacizumab, two cycles of ivonescimab-a first-in-class programmed cell death protein receptor-1 (PD-1)/vascular endothelial growth factor-A (VEGF-A) bispecific antibody-induced significant regression of pulmonary target lesions (PR), sustained over six cycles with minimal toxicity...While the rapid PR and favorable safety profile are promising, longer follow-up is required to assess durability and survival benefits. These findings underscore the need for further investigation of bispecific antibodies in precision oncology paradigms for multi-refractory EGFR-driven NSCLC."

IO biomarker • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • PD-1 • PD-L1 • TP53

BI08 A prospective observational study exploring the incidence and impact of cutaneous toxicities in patients undergoing oncological treatment. (PubMed, Br J Dermatol) - "The most frequently observed immunotherapy agent causing cutaneous toxicity was pembrolizumab (20%). Cetuximab and bevacizumab were the most common culprit targeted therapies (both 7%)...Cutaneous toxicities may impact on QoL. Decisions regarding alterations to treatment plans due to cutaneous toxicities should be made in collaboration by oncologists and dermatologist."

Journal • Observational data • CNS Disorders • Dermatology • Eosinophilia • Lung Cancer • Melanoma • Oncology • Psychiatry • Solid Tumor • Steven-Johnson Syndrome

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=72 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1/2 trial • Oncology • Prostate Cancer • Solid Tumor

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2026 ➔ Jan 2029 | Trial primary completion date: Nov 2025 ➔ Jul 2027

Trial completion date • Trial primary completion date • Infectious Disease • Oncology • Respiratory Diseases • Squamous Cell Carcinoma

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2 | N=169 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Jan 2025

Trial completion • Trial completion date • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • BRAF

COLUMBIA 1: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (clinicaltrials.gov) - P1/2 | N=61 | Active, not recruiting | Sponsor: MedImmune LLC | Trial completion date: Nov 2025 ➔ Nov 2026

Trial completion date • Colorectal Cancer • Oncology • Solid Tumor

Tisotumab vedotin vs investigator's choice of chemotherapy as second- or third-line (2L/3L) treatment for Chinese patients (pts) with recurrent or metastatic cervical cancer (r/mCC) in innovaTV 301 (ESMO Asia 2025) - P3 | "This report presents the first analysis of efficacy and safety of TV in Chinese pts with r/mCC, based on data from both global and China extension portions within innovaTV 301. Eligible pts had r/mCC with disease progression following standard chemotherapy doublet ± bevacizumab ± anti-PD-(L)1 therapy, measurable disease per RECIST v1.1, and an ECOG performance status of 0-1. Pts were randomised 1:1 to receive TV monotherapy or investigator's choice of topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed... TV as 2L/3L treatment demonstrated clinically meaningful improvements in OS, PFS, and ORR vs chemotherapy, with a manageable safety profile, for Chinese pts with r/mCC."

Clinical • Metastases • Cervical Cancer • Oncology • Solid Tumor

Iparomlimab and tuvonralimab (QL1706) vs zimberelimab for previously treated recurrent/metastatic cervical cancer (r/mCC): An unanchored matching-adjusted indirect comparison (MAIC) (ESMO Asia 2025) - P2 | "For efficacy and safety analysis, adjustments were made for age, histologic type, Eastern Cooperative Oncology Group (ECOG) performance status (PS), combined positive score (CPS), prior treatment lines, prior bevacizumab use and prior radiotherapy. After matching, QL1706 had effective sample sizes (ESS) of 90 for efficacy and 90.2 for safety analyses. These findings indicate that QL1706 demonstrated favourable efficacy and a comparable safety profile compared to zimberelimab for previously treated r/mCC patients. QL1706 could potentially serve as a new standard treatment option for this population."

Metastases • Cervical Cancer • Oncology • Solid Tumor • PD-L1

A 66-Year-Old Woman with EGFR-Mutant Lung Adenocarcinoma and Brain Metastases Achieving 96-Month Overall Survival with serially deploying three distinct third-generation EGFR-TKIs (ESMO Asia 2025) - "First-line icotinib plus paclitaxel/nedaplatin was given and achieved PR and 36-month PFS...Osimertinib 80mg qd combined with pemetrexed chemotherapy for 5 cycles, followed by osimertinib monotherapy, yielded 25-month PFS until isolated CNS progression. Despite concomitant whole-brain radiotherapy and bevacizumab with Osimertinib, intracranial lesions advanced...This exceptional survival in advanced EGFR+ NSCLC was achieved through initial chemo-TKI therapy, sequential third-generation TKIs (osi→almo→furmo) for CNS control, and furmonertinib dose escalation for late CNS progression. The persistent TP53 co-mutation suggests a resistance mechanism, while PD-L1 negativity excluded immunotherapy, demonstrating the efficacy of optimized TKI sequencing alone."

Clinical • IO biomarker • Brain Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1 • TP53

Efficacy and safety of bevacizumab combined with immune checkpoint inhibitors in advanced NSCLC: A systematic review of clinical trials (ESMO Asia 2025) - "Bevacizumab combined with ICI-based chemotherapy demonstrates a potential to improve clinical outcomes in advanced NSCLC, especially in select patient subgroups. However, benefits should be interpreted in the context of increased toxicity. Further studies are warranted to clarify patient selection criteria and optimize risk–benefit balance."

Checkpoint inhibition • Clinical • Metastases • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Bevacizumab-chemotherapy versus immunotherapy-chemotherapy in advanced PD-L1- negative lung adenocarcinoma: A real-world retrospective cohort analysis (ESMO Asia 2025) - "Chemotherapy combined with bevacizumab demonstrated non-inferior PFS and OS compared to chemotherapy combined with immunotherapy in advanced lung adenocarcinoma patients with negative driver genes mutations and PD-L1 expression. Moreover, NSCLC patients with high baseline LIPI scores are intend to derive greater benefits from chemoimmunotherapy regimens."

IO biomarker • Metastases • Real-world • Real-world evidence • Retrospective data • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • HER-2 • KRAS • PD-L1

Impact of adding bevacizumab to erlotinib on progression-free and overall survival in EGFR-mutant advanced NSCLC with brain metastases: A meta-analysis (ESMO Asia 2025) - "In EGFR-positive advanced NSCLC patients with brain metastases, adding bevacizumab to erlotinib significantly improves progression-free survival (PFS) but does not provide a clear overall-survival (OS) benefit. This combination therapy represents an effective option to delay disease progression in this high-risk population. Further studies with longer follow-up are needed to determine its long-term impact on survival and quality of life."

Metastases • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Real world efficacy and safety of continuing anlotinib plus standard-of-care treatment beyond disease progression in patients with advanced non–small cell lung cancer (ESMO Asia 2025) - "Background: Previous studies did not demonstrate survival benefit of continued bevacizumab treatment beyond disease progression (PD) in advanced NSCLC. Our study demonstrated that there is a favorable survival benefit of continuing anlotinib treatment beyond PD in patients with NSCLC. To our knowledge, this study is the first large-scale real-world clinical data of Anlotinib across multiple lines of treatment beyond PD in NSCLC."

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Efficacy and influencing factors of immunotherapy for EGFR Exon 20 Insertion (ESMO Asia 2025) - "The efficacy of immune checkpoint inhibitors (ICIs) in these patients—including vs EGFR-sensitive mutations and key influencing factors—remains unclear. We analyzed 163 metastatic adenocarcinoma patients with EGFR ex20ins, 19del, or 21 L858R mutations who received ICI monotherapy or combinations (ICI+chemo, ICI+chemo+bevacizumab)... ICI efficacy in EGFR ex20ins NSCLC differs from EGFR-sensitive mutations, with responses influenced by genomic (ex20ins subtype, TMB) and PD-L1 expression. Despite more neoantigens, their weak binding affinity may limit immunogenicity, guiding personalized ICI use in ex20ins patients."

Clinical • EGFR exon 20 • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • PD-L1 • TMB

Osimertinib versus erlotinib plus an angiogenesis inhibitor for patients with EGFR-mutated non-small cell lung cancer and pleural effusion (ESMO Asia 2025) - "PFS of MPE (MPE-PFS), PFS, and overall survival (OS) were calculated using Kaplan-Meier curves, and log-rank tests were performed. Of 421 patients, median age was 73 years [range 28-92], 272 (65%) female, performance status 0 or 1 in 334 (79%) cases, adenocarcinoma in 417 (99%) cases, and 373 (89%) received osimertinib, 48 (11%) received erlotinib plus bevacizumab or ramucirumab (E/VEGF group). In patients with EGFR-mutated NSCLC and MPE, osimertinib was shown to be equally effective as erlotinib plus an angiogenesis inhibitor in controlling MPE."

Clinical • Pleural effusion • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR